Domestic 2nd ADC drug Takeda target CD30 approved for listing!

REVIEW: approved indications for adults between CD30 positive relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) and relapsed or refractory classical Hodgkin's lymphoma treatment (cHL) ofTakeda China today announced that its innovative drugs targeting comfortable advantage (for injection cloth rituximab) formally approved by the State Drug Administration to enter China, approved indications for adults CD30 positive relapsed or refractory systemic anaplastic large inter-cell lymphoma (sALCL) and relapsed or refractory classical Hodgkin lymphoma (cHL) treatmentcomfortable Profit (rituximab injection SHEET) of monoclonal antibody targeting the CD30 cell connecting method of inhibiting microtubule drugs (monomethyl auristatin E, MMAE) composition, may be in the blood in stable, precise killing tumor cells expressing CD30The product is rich clinical experience, full real-world evidence-based, proven efficacyEarlier, the National Comprehensive Cancer Network (NCCN) guidelines have recommended rituximab cloth as the standard therapy, Chinese Society of Clinical Oncology (CSCO) will also incorporate clinical guidelines range of optionscomfortable Profit (injection SHEET rituximab) in China is approved data SG035-0003, C25007 based on three clinical studies SG035-0004,Wherein, the SG 035-0004-study, for inter relapsed or refractory anaplastic large cell lymphoma, 58 cases among 97% of patients with relapsed or refractory systemic anaplastic large cell lymphoma achieved tumor shrinkage, 5-year survival rate increased to 60%; in SG035-0003 study, 94% of patients with relapsed or refractory classical Hodgkin lymphoma can achieve tumor shrinkage, median overall survival (OS) from 27.6 history months up to 40.5 months; C25007 in the study had received at least one sheet to the start of chemotherapy and rituximab treatment is not suitable for stem cell transplantation (SCT) or multidrug chemotherapy relapsed or refractory classical Hodgkin's lymphoma patients (n = 60), the objective response rate (ORR) was 50% (95% CI, 37: 63%)lymphoma is originated in hematopoietic and lymphoid malignancies, are 70 different subtypes "lymphoma family" collectivelyCurrently, lymphoma has one of the highest of China's top ten cancer mortalityData show that China has about 9.3 million people are diagnosed with lymphoma each year, more than 50,000 people die from cancer every yearAt present, for the inter-relapsed or refractory systemic anaplastic large cell lymphoma and classical Hodgkin's lymphoma treatment is limited, the living conditions of the patient is not optimistica Editor: MengmengRelated tags:a country, Takeda0< br /> 0